Roche at EBF 2026

Nov 17–19, 2026 Barcelona, Spain ~800 attendees Website

Roche brings 9 presentations to EBF 2026 in Barcelona. Its program ranges across biomarkers, assay lifecycle management and protein LC–MS, with work on immunogenicity testing and sample handling. One case covers keeping cerebrospinal fluid PK data intact as studies move from first-in-human to multi-site trials.

Organization	EBF 2026 Attendance
Roche Basel, Switzerland
roche.com Pharma Pharmaceutical and diagnostics group developing medicines in oncology, immunology, neuroscience and ophthalmology, alongside its Roche Diagnostics business.	Talk Tue Nov 17 11:30–11:50am Part of Session 2: Smarter Workflows: From Implementation to Scientific Confidence Clinical Speed meets GLP Rigor: Upgrading an IVD Immunoanalyzer for High-Throughput PK/PD Analysis in a Bioanalytical Laboratory - Lessons Learnt Automation & AI · Ligand binding Talk Tue Nov 17 2:40–3pm Part of Session 5: Expanding LC–MS Bioanalysis: New Modalities, Advanced Workflows and Multi-Omics LC-MS Bioanalysis of Lipid Conjugated siRNAs: Analytical Challenges and Novel Approaches New modalities · LC–MS Talk Tue Nov 17 5:20–5:40pm Part of Session 7: BM CoU in practice Navigating Soluble Biomarker Complexity: Challenges, Assay Strategy, and Case Studies Biomarkers Talk Wed Nov 18 9–9:20am Part of Session 10: Bioanalysis Beyond Conventional Matrices From First-in-Human to Multi-Site Trials: Practical Bioanalytical Strategies to Preserve CSF Pharmacokinetic Data for Highly Adsorptive Molecules Sampling Talk Wed Nov 18 9:20–9:40am Part of Session 12: Assay life cycle Assay Lifecycle in Practice: Strategic Stewardship, Change Control, and Revalidation Case Studies Regulation Talk Wed Nov 18 9:40–10am Part of Session 10: Bioanalysis Beyond Conventional Matrices Operationalizing Unstable Biomarkers: How Biosample Operations and Bioanalysis Enable Successful Scale-Up from Single-Site to Multi-Site Clinical Trials Biomarkers · Sampling Talk Wed Nov 18 5–5:20pm Part of Workshop 10: ADA - Adaptive Tier Overcoming the 3-Tier ADA Testing Paradigm via Mechanistic Assay Understanding Immunogenicity Talk Thu Nov 19 9:20–9:40am Part of Session 16: Protein MS tech 1 A Multiplexed LC-MS/MS Strategy for the Simultaneous Quantification of a Transgene Protein and its Endogenous Counterpart in a Gene Therapy Program. LC–MS Talk Thu Nov 19 11:30–11:50am Part of Session 20: Pushing the Limits of Sensitivity and Multiplexing in Bioanalysis Navigating High-Plex Profiling and Targeted Quantification in Drug Development Biomarkers

Organization

EBF 2026 Attendance

Roche

Basel, Switzerland

roche.com

Pharma

Pharmaceutical and diagnostics group developing medicines in oncology, immunology, neuroscience and ophthalmology, alongside its Roche Diagnostics business.

Talk

Tue Nov 17
11:30–11:50am

Part of Session 2: Smarter Workflows: From Implementation to Scientific Confidence

Clinical Speed meets GLP Rigor: Upgrading an IVD Immunoanalyzer for High-Throughput PK/PD Analysis in a Bioanalytical Laboratory - Lessons Learnt

Automation & AI · Ligand binding

Talk

Tue Nov 17
2:40–3pm

Part of Session 5: Expanding LC–MS Bioanalysis: New Modalities, Advanced Workflows and Multi-Omics

LC-MS Bioanalysis of Lipid Conjugated siRNAs: Analytical Challenges and Novel Approaches

New modalities · LC–MS

Talk

Tue Nov 17
5:20–5:40pm